Anti-Rheumatic Rx
Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining. Many people missed the last day (June 3rd) of the meeting as a pending Milan airport strike on June 4th dictated last-minute changes to travel and learning. Here are a few of my favorite abstracts from the Late Breaker Session.
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias. At EULAR 2023 in Milan, the perfect platform was provided for an airing of grievances, in a debate entitled ‘Clinically suspect arthralgias: fact or myth’.
David Liew drdavidliew
2 years ago
Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation.
The better we can predict these patients, the more we can get the right therapy early
POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505
Dr. Antoni Chan synovialjoints
2 years ago
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Bella Mehta bella_mehta
2 years ago
meds for PsA at #EULAR2023 recommendations
bDMARD after csDMARD (no order proposed)
@RheumNow https://t.co/bHMG4A8nmP
Aurelie Najm AurelieRheumo
2 years ago
How do we improve MTX adherence?
Biochemical measure of MTX adherence
37% of patients starting a biologic do not take their MTX (!)
Those who do respond better to first Biologic at 6 Mo than those who don’t
37% biologic responders = non adherent
POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
David Liew drdavidliew
2 years ago
The key data for treating clinically suspect arthralgias (CSA):
TREAT-EARLIER (MTX)
ARIAA, APIPPRA (abatacept)
but what we need to do going forward:
stratify pts better for studies
predict individual risk better, to weight up risk-benefit of intervention
#EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
Dr. John Cush RheumNow
2 years ago
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. Antoni Chan synovialjoints
2 years ago
Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form of MTX-PG, low FPGS activity resulting in lower capacity to form MTX-PG, Perez-Garcia LF, Abst#OP0224 #EULAR2023 @RheumNow https://t.co/8sGQOBxn8r
Poster Hall